Close Menu

NEW YORK — Enlighta said today that it has partnered with Chinese bioinformatics firm LHHC Medical Technology to market an artificial intelligence-based blood test system for early cancer detection.

The system, called No Cancer, is designed to analyze data from routine blood and biochemistry tests against a large dataset of anonymized individuals of Asian descent to identify immunological abnormalities that indicate a high risk of 13 different cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.


This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.